AGSAVI vs Valsartan/amlodipine/chlorthalidone (AJU-C52)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Hypertension

Shared mechanism: Angiotensin II receptor / Calcium channel / Thiazide-like diuretic · full Hypertension pipeline

AGSAVI

Marketed by Ahn-Gook Pharmaceutical

Phase 3 in Hypertensionsmall molecule (combination)
Partial signal

NCT05503953 · Phase 3 · completed

The study was randomized, double-blind, and active-controlled, with 318 participants, and evaluated a clinical blood-pressure endpoint. Because the registry does not report whether the primary comparison was statistically significant, the findings cannot be classified as demonstrating a positive effect.

No aligned efficacy figure on record for this race.

Valsartan/amlodipine/chlorthalidone (AJU-C52)

Developed by AJU Pharm

Phase 3 in Hypertensionsmall molecule (combination)
Reliable signal

NCT06416865 · Phase 3 · completed

The trial was randomized with full blinding of participants, care providers, investigators, and outcome assessors, used an active dual-therapy comparator, enrolled a reasonably sized cohort for a blood-pressure trial, and measured a hard, disease-defining physiological endpoint (systolic blood pressure change) rather than a lab biomarker. A sourced result shows the triple-combination arm achieved a clearly favorable and clinically meaningful reduction in blood pressure versus the active comparator, meeting the primary endpoint.

Reported efficacy

Changes in MSSBP(mean sitting systolic blood pressure) (8th week): Change in MSSBP from baseline to week 8: between-group difference of -10.99 (valsartan/amlodipine/chlorthalidone vs valsartan/amlodipine control) (met)

Result source: NCT06416865

Results for Hypertension

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAGSAVIValsartan/​amlodipine/​chlorthalidone (AJU-C52)
Seated SBP, change—Not posted · NCT05503953—Not posted · NCT06416865
24-hour ambulatory SBP, change—Not posted · NCT05503953—Not posted · NCT06416865
Seated DBP, change—Not posted · NCT05503953—Not posted · NCT06416865

Seated SBP, change

AGSAVI
—Not posted · NCT05503953
Valsartan/​amlodipine/​chlorthalidone (AJU-C52)
—Not posted · NCT06416865

24-hour ambulatory SBP, change

AGSAVI
—Not posted · NCT05503953
Valsartan/​amlodipine/​chlorthalidone (AJU-C52)
—Not posted · NCT06416865

Seated DBP, change

AGSAVI
—Not posted · NCT05503953
Valsartan/​amlodipine/​chlorthalidone (AJU-C52)
—Not posted · NCT06416865
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

AGSAVI: no structured comparison results are available for Hypertension.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Valsartan/amlodipine/chlorthalidone (AJU-C52)
Change in MSSBP from baseline to week 8: between-group difference of -10.99 (valsartan/amlodipine/chlorthalidone vs valsartan/amlodipine control) NCT06416865 · Phase 3 · design grade: strong · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AGSAVI's landscape · Valsartan/amlodipine/chlorthalidone (AJU-C52)'s landscape